Journal of Clinical Endocrinology & Metabolism, Vol 61, 152-159, Copyright © 1985 by Endocrine Society

ARTICLES

Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist

DA Harris, G Van Vliet, CA Egli, MM Grumbach, SL Kaplan, DM Styne and M Vainsel

To explore further the relationship of gonadal sex steroids to the rise in somatomedin-C (Sm-C) during puberty, we studied a group of children with true precocious puberty before and after treatment which suppressed sex steroid output. Plasma estradiol and testosterone and serum acid-ethanol-extractable Sm-C were determined by specific RIAs in 7 boys and 12 girls with true precocious puberty before and at regular intervals during treatment with a potent LHRH-agonist (LHRH-A), D-Trp6- Pro9-NEt-LHRH. For comparison, Sm-C and sex steroid concentrations were determined in 266 normal adolescents and 37 normal prepubertal children, 1-9 yr of age. The mean +/- SEM Sm-C levels in normal male individuals peaked at 15 yr (2.46 +/- 0.23 U/ml) and at pubertal (genital) stage III (2.29 +/- 0.19 U/ml), and those in normal females reached their highest concentration at 12-15 yr of age and at pubertal (breast) stage III (2.47 +/- 0.15 U/ml). Sm-C concentrations correlated better with pubertal (genital or breast) stage than with chronological age for both sexes and better with testosterone levels in males than with estradiol levels in females. The mean +/- SEM Sm-C concentrations in both males and females with true precocious puberty were 2.07 +/- 0.16 U/ml before therapy and decreased significantly to 1.52 +/- 0.13 U/ml after 6 months of therapy. The mean Sm-C level of the patients remained significantly elevated for chronological age, but decreased into the normal range for bone age after 6-12 months of therapy. Sm-C correlated significantly with testosterone and estradiol levels, but not with growth rate. Mean nighttime GH secretion decreased significantly after 6 months of LHRH-A therapy. In summary, children with true precocious puberty have Sm-C elevations typical of normal puberty. The decrease in Sm-C levels after suppression of gonadal sex steroid output with LHRH-A is evidence that sex steroids are necessary to induce this elevation in Sm-C concentration. The decrease in GH secretion during LHRH-A therapy suggests that the effect of sex steroids on Sm-C levels during normal puberty is mediated, at least in part, through stimulation of GH secretion.

This article has been cited by other articles:

				C. Maffeis, R. Franceschi, P. Moghetti, M. Camilot, S. Lauriola, and L. Tato Circulating ghrelin levels in girls with central precocious puberty are reduced during treatment with LHRH analog Eur. J. Endocrinol., January 1, 2007; 156(1): 99 - 103. [Abstract] [Full Text] [PDF]

				K.-C. Leung, G. Johannsson, G. M. Leong, and K. K. Y. Ho Estrogen Regulation of Growth Hormone Action Endocr. Rev., October 1, 2004; 25(5): 693 - 721. [Abstract] [Full Text] [PDF]

				J.-C. Carel, N. Lahlou, M. Roger, and J. L. Chaussain Precocious puberty and statural growth Hum. Reprod. Update, March 1, 2004; 10(2): 135 - 147. [Abstract] [Full Text] [PDF]

				M. Weise, A. Flor, K. M. Barnes, G. B. Cutler Jr., and J. Baron Determinants of Growth during Gonadotropin-Releasing Hormone Analog Therapy for Precocious Puberty J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 103 - 107. [Abstract] [Full Text] [PDF]

				M. Cisternino, M. Draghi, S. Lauriola, D. Scarcella, S. Bernasconi, L. Cavallo, F. De Luca, A. Lomeo, and L. Tato The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor-Binding Protein Complex in Girls with Central Precocious Puberty before and during Gonadotropin-Releasing Hormone Analog Therapy J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4629 - 4633. [Abstract] [Full Text] [PDF]

				J. V. Zborowski, J. A. Cauley, E. O. Talbott, D. S. Guzick, and S. J. Winters Bone Mineral Density, Androgens, and the Polycystic Ovary: The Complex and Controversial Issue of Androgenic Influence in Female Bone J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3496 - 3506. [Full Text]

				R. Marcus, D. Leary, D. L. Schneider, E. Shane, M. Favus, and C. A. Quigley The Contribution of Testosterone to Skeletal Development and Maintenance: Lessons from the Androgen Insensitivity Syndrome J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1032 - 1037. [Abstract] [Full Text]

				Is Obesity an Outcome of Gonadotropin-Releasing Hormone Agonist Administration? Analysis of Growth and Body Composition in 110 Patients with Central Precocious Puberty J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4480 - 4488. [Abstract] [Full Text]

				E. C. Walvoord and O. H. Pescovitz Combined Use of Growth Hormone and Gonadotropin-releasing Hormone Analogues in Precocious Puberty: Theoretic and Practical Considerations Pediatrics, October 1, 1999; 104(4): 1010 - 1014. [Abstract] [Full Text]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				M. E. Wilson Regulation of the Growth Hormone-Insulin-Like Growth Factor I Axis in Developing and Adult Monkeys Is Affected by Estradiol Replacement and Supplementation with Insulin-Like Growth Factor I J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2018 - 2028. [Abstract] [Full Text]

				F. I. Sharara and L. C. Giudice Role of Gorwth Hormone in Ovarian Physiology and Onest of Puberty Reproductive Sciences, January 1, 1997; 4(1): 2 - 7. [Abstract] [PDF]